

## Book Reviews

**Editorial Policy.** Recently published books and journals (one copy) are invited by the Editorial Office for announcement and review in ANTICANCER RESEARCH (no fee). Each announcement should include the full title of the publication, authors or editors, the number of pages, price, year of publication, ISBN and publisher. Publishers will be notified upon receipt of books and tear sheets of reviews will be sent after publication. Books will be returned to the sender only if the announcement is rejected. Reviews will be objective and clear regarding the content, quality and usefulness of the publication.

### Human Monoclonal Antibodies. Methods and Protocols.

*Edited by M. Steinitz.*

2019, pp 483, EUR 176.79, ISBN: 978-1-4939-8957-7.  
Springer Science+Business Media, New York, NY, USA.

This second edition volume expands on the previous edition with descriptions of recent developments in the field. The chapters in this book cover topics such as monoclonal antibodies for the treatment of melanoma; production and purification of human monoclonal antibodies; humanization and optimization of monoclonal antibodies; rapid chimerization of monoclonal antibodies; epitope mapping via phage display from single gene libraries; recombinant antibodies made by combining phage and yeast display selections; production of stabilized antibody fragments in the *E. coli* bacterial cytoplasm and transfected mammalian cells; and analysis of CAR T cells. Written in the highly successful *Methods in Molecular Biology* series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

*Human Monoclonal Antibodies: Methods and Protocols, Second Edition* is a valuable tool for novice and expert researchers interested in learning more about this evolving field.

### Biobanking. Methods and Protocols.

*Edited by W.H. Yong.*

2019, pp 448, EUR 176.79, ISBN: 978-1-4939-8933-1.  
Springer Science+Business Media, New York, NY, USA.

This volume not only discusses various common biobanking topics, it also delves into less-discussed subjects such as what is needed to start a biobank, training of new biobanking personnel, and ethnic representation in biospecimen research. Other chapters in this book

span practical topics including: disaster prevention and recovery; information technology; flora and fauna preservation including zoological fluid specimen photography; surgical and autopsy biobanking; biobanking of bodily fluids; biosafety; cutting frozen sections; immunohistochemistry; nucleic acid extraction; and biospecimen shipping. Written in the highly successful *Methods in Molecular Biology* series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

*Biobanking: Methods and Protocols* is a valuable resource for novice and practicing biobankers, and for end-user researchers. This book aims to bring new insight into the field and expand on current biomedical biobanking studies.

### Immunotherapy.

*Edited by A. Naing, J. Hajar.*

2019, pp 182, EUR 135.19, ISBN: 978-3-030-02504-5.  
Springer International Publishing AG, Cham, Switzerland.

The second edition of *Immunotherapy* is an updated overview of immuno-oncology in acute myeloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects.

This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions.

Edited by two renowned experts in the field, the book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.